We’ve been pounding the table over obesity drug stocks for quite some time, we said on December 10. Look at Structure Therapeutics (GPCR). The first time we highlighted an opportunity in the stock, it traded at around $22 in late June. Today, it’s up to $78.50.

Hidden trigger points that hardly anyone knows about illuminate the runaway winners. Click here to learn how to spot the trigger points and cash in.

Driving the stock higher, there’s a good deal of excitement about the initiation of its first-in-human Phase 1 clinical study of ACCG-2671, the company’s lead oral small molecule amylin receptor agonist for the treatment of obesity. 

Plus, not long ago, Genentech entered a $100 million deal with GPRC subsidiary Gasherbrum Bio. The deal grants Genentech rights for certain GPCR patents related to CT-996, an investigational small-molecule GLP-1 agonist in clinical development for type 2 diabetes and obesity, showing promising weight loss in early trials.

Sincerely,

Ian Cooper